Introduction {#sec1}
============

Injury to the medial collateral ligament (MCL) of the knee is the most common knee ligament injury that occurs mainly in young individuals during sports activity.[@bib1], [@bib2] MCL injury, even acute Grade 3 injury, can heal by nonoperative treatment.[@bib3], [@bib4] It generally takes 5--7 weeks for athletes to heal and return to full competition under a well-controlled rehabilitation programme.[@bib5] However, some cases do not heal and lead to continuous instability, subsequently causing dysfunction of the knee joint. Novel strategies for more effective and early healing of MCL injury by nonoperative treatment should be developed.

Recently, the importance of micro-ribonucleic acid (miRNA) in the pathogenesis of human diseases such as cancers, heart diseases, and neuron disorders has been recognised. These miRNAs are a set of approximately 22-nucleotide, small noncoding RNAs that negatively regulate gene expressions through binding to the 3′ untranslated region of mRNA of their target genes.[@bib6], [@bib7] The miRNAs play a crucial role in various cellular processes such as cell proliferation, differentiation, and apoptosis, which result in tissue specialisation and homeostasis. Therefore, an abnormal expression of miRNAs has been linked to several diseases.[@bib8], [@bib9], [@bib10], [@bib11] Therapeutic trials to regulate endogenous expression of miRNA *in vivo* by administration of synthetic miRNA or antisense miRNA with some modifications have been reported.[@bib12], [@bib13], [@bib14] Lanford et al[@bib15] demonstrated the successful treatment of chimpanzees with hepatitis C virus infection by the administration of a locked nucleic acid-modified oligonucleotide complementary to miR-122. Thus, the therapeutic strategy targeting miRNAs is a novel and promising avenue to treat human diseases.

Angiogenesis has been recognised as an important initiator of healing and remodelling of tissues including ligaments.[@bib16], [@bib17], [@bib18] Several reports demonstrated induction of angiogenesis/vasculogenesis by administration of drugs, cytokines, and cells to the injured ligaments.[@bib19], [@bib20], [@bib21], [@bib22] A well-known potent factor of angiogenesis is miRNA (miR)-210. It is upregulated in endothelial cells in response to hypoxia, which affects cell survival, migration, and differentiation; even in normoxic condition, overexpression of miR-210 could induce the formation of capillary-like structures with vascular endothelial growth factor (VEGF)-driven cell migration.[@bib23], [@bib24], [@bib25] It has been reported that local administration of miR-210 can promote tissue healing *in vivo*.[@bib26], [@bib27] Therefore, we hypothesised that local injection of synthetic miR-210 into the injured MCL could accelerate ligament healing. The purpose of this study is to examine the effect of local injection of synthetic miR-210 on the acceleration of ligament healing in a rat MCL injury model.

Materials and methods {#sec2}
=====================

All procedures were performed according to the guidelines for animal experimentation of Hiroshima University, and with the approval of the Committee of Research Facilities for Laboratory Animal Sciences, Graduate School of Biomedical Sciences, Hiroshima University.

Preparation of double-stranded RNA {#sec2.1}
----------------------------------

Double-stranded (ds) miR-210 (sequences 66-CUG-UGC-GUG-UGA-CAG-CGG-CUG-A-87 and 87-AGC-CCC-UGC-CCA-CCG-CAC-ACU-G-66; B-Bridge International, Mountain View, CA, USA) and ds control RNA \[sequences 51-ATC-CGC-GCG-ATA-GTA-CGT-A-31 and 31-overhang dTdT/dTdT (sense/antisense) siRNA negative control; B-Bridge International\] were prepared for the local injection according to a previous report.[@bib27] The dsRNA was mixed with atelocollagen, which is a highly purified collagen type 1 isolated from calf dermis by pepsin treatment (Koken, Tokyo, Japan). Equal volumes of atelocollagen (10 μL) as a carrier of dsRNA and dsRNA solution (20 μg/10 μL) were combined and mixed by rotation at 4°C for 20 minutes, and a total of 20 μL dsRNA--atelocollagen complex was injected into the injured site of MCL.

Animal model {#sec2.2}
------------

Twelve-week-old male Sprague-Dawley rats were used in this study. A total of 41 rats were anaesthetised with an intraperitoneal injection of 1 mL/kg pentobarbital sodium. Medial skin incision was applied at the right knee joint of the rats, and the MCL was cut transversely using a scalpel. The fascia and skin were sutured, and briefly, the dsRNA--atelocollagen complex was injected into the injured site of MCL. Twenty-one rats (control animals) were given ds control RNA injection, and another 21 rats were assigned to the miR-210-treated group. Five rats, on which sham surgery was performed, were used for mechanical testing.

Histological analysis {#sec2.3}
---------------------

At 2 weeks and 4 weeks after injection, 10 rats in each group (2 weeks, 5 rats; 4 weeks, 5 rats) were sacrificed by an overdose of anaesthesia. The MCL was harvested and embedded in optical cutting temperature compound (Sakura Finetek USA, Inc., Torrance, CA, USA). Frozen serial sections of 6 μm thickness were prepared and Masson trichrome staining was performed. All specimens were given a histological score from 0 to 6 according to the following parameters: degree of retraction, tissue coverage, predominant cell type, and collagen fibre organisation as described previously.[@bib28] All specimens were evaluated by two authors (T.N. and M.A.U.) without any knowledge of treatment, in a blinded fashion.

Mechanical testing {#sec2.4}
------------------

The ultimate failure loads of the MCL in both groups (*n* = 5) at 2 weeks and 4 weeks, and the sham group (*n* = 5) were measured using a conventional tensile tester (1840NT/500; AIKOH Engineering, Osaka, Japan). All specimens were dissected free of all skin, subcutaneous muscle, ligament, and menisci, leaving the MCL. The dissected specimens were set into a cylinder of polymethylmethacrylate cement so that the load was directed along the longitudinal axis of the MCL. The ultimate failure load was measured at a cross-head speed of 200 mm/minute until the femur--MCL--tibia complex failed. Normal ligaments of the rats that received sham operation used as the basic standard.

Immunohistochemistry {#sec2.5}
--------------------

For immunofluorescence staining of VEGF, isolectin B4, collagen type 1, and Ki67, frozen sections at 2 weeks were fixed with 4.0% paraformaldehyde at 4°C for 5 minutes, and stained with rabbit polyclonal anti-VEGF (Abcam, Cambridge, MA, USA), fluorescein-labelled GSL I-isolectin B4 (Vector Laboratories, Burlingame, CA, USA), rabbit anti-Ki67 (Neomarkers, Fremont, CA, USA), and goat polyclonal anticollagen type 1 antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA). The secondary antibodies were Alexa Fluor 568-conjugated goat antirabbit immunoglobulin G for VEGF and Ki67, and Alexa Flour 488-conjugated rabbit antigoat immunoglobulin G for collagen type 1 (all from Molecular Probes/Invitrogen, Carlsbad, CA, USA). DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride) solution was applied for 5 minutes to detect nuclear staining.

For the evaluation of newly formed vessels in the MCL, five microscopic areas (250 μm × 250 μm) from each specimen at 200× magnification were randomly chosen (*n* = 5 in each group). Capillaries were recognised as isolectin B4-positive tubular structures and counted by the two authors (T.N. and M.A.U.).

Microarray analysis {#sec2.6}
-------------------

Total RNA for DNA microarray was extracted from the repaired site in each group using TRIzol (Life Technologies, Carlsbad, California, USA), according to the manufacturer\'s instructions. One microgram of the total RNA was used for the DNA microarray analysis. After amplification, the RNA sample in each group (*n* = 1 in each group) was labelled with Cy3 or Cy5, and hybridised with 3D-Gene Rat Oligo chip 24k (Toray Industries Inc., Tokyo, Japan). After hybridisation, hybridisation signals were scanned using 3D Gene Scanner 3000 (Toray Industries Inc.), and all the data from scanned images were scaled by global normalisation. From microarray data, the differentially expressed genes during MCL healing were analysed by gene ontology and pathway enrichment analysis. Gene ontology analysis was performed using GeneCodis2.0 software to integrate differentially expressed genes and to evaluate groups of genes with similar biological function.[@bib29], [@bib30], [@bib31] GenMAPP (gene map annotator and pathway profiler), which allows us to view and analyse microarray data on biological pathways, was also used[@bib32] to identify which pathways are affected by miR-210 during MCL healing.

Statistical analysis {#sec2.7}
--------------------

The Mann--Whitney *U* test was used for the detection of differences in the histological scores and vessel numbers between the two groups, and multiple comparisons in the mechanical testing were performed using the Tukey--Kramer\'s *post hoc* test. A *p* value of \< 0.05 was considered statistically significant.

Results {#sec3}
=======

Macroscopic observation {#sec3.1}
-----------------------

At 2 weeks after local injection, the fibres in the miR-210-treated group were macroscopically observed to be continuous and bulkier as compared to the control group. In the control group, the resected area of MCL was filled with scar tissues. At 4 weeks, the repaired site of MCL in the control group was thinner than that in the miR-210-treated group ([Figure 1](#fig1){ref-type="fig"}A).Figure 1(A) Gross appearance of medial collateral ligament (MCL). Arrow indicates the injured site of MCL. (B) Masson trichrome staining of MCL in both groups. Bar indicates 200 μm. (C) Histological score of both groups. \**p* \< 0.05. miR-210 = microRNA-210.

Histological analysis {#sec3.2}
---------------------

Histological analysis using Masson trichrome staining revealed that parallel fibres in the injured site were organised at 2 weeks and became thicker at 4 weeks in the miR-210-treated group, as compared to the control group. On the other hand, the injured sites in the control group were filled with loose fibrous tissues and were thinner than those in miR-210-treated group ([Figure 1](#fig1){ref-type="fig"}B). The histological score of tissue samples from the miR-210-treated group was significantly higher than that from the control group at 2 weeks (1.6 ± 2.2 vs. 5.6 ± 0.54) and 4 weeks (4.5 ± 0.5 vs. 5.8 ± 0.4; [Figure 1](#fig1){ref-type="fig"}C). A mechanical test showed that the ultimate failure load in the miR-210-treated group (19.8 ± 2.7 N) was significantly higher than that in the control group (7.5 ± 3.4 N) at 2 weeks, but it was significantly lower than that in the sham group (32.9 ± 1.2 N; *p* \< 0.05). At 4 weeks, there was no significant difference of the ultimate failure load between the miR-210-treated group (39.8 ± 5.5 N) and the control group (33.7 ± 8.3 N), although the ultimate failure load in the miR-210-treated group was likely to be higher than that in the control group (*p* = 0.14; [Figure 2](#fig2){ref-type="fig"}).Figure 2Ultimate failure load of medial collateral ligament (MCL). \**p* \< 0.05. miR-210 = microRNA-210.

Immunofluorescent staining {#sec3.3}
--------------------------

To examine the angiogenesis during MCL healing, isolectin B4 staining was performed to detect the blood vessels. At 2 weeks, abundant blood vessels in the repaired tissues were observed in the miR-210-treated group as compared to the control group ([Figure 3](#fig3){ref-type="fig"}A). The number of blood vessels in the repaired tissues of the miR-210-treated group (158.1 ± 11.5/mm^2^) was significantly higher than that in the control group (72 ± 6.1/mm^2^; *p* \< 0.05; [Figure 3](#fig3){ref-type="fig"}B). Immunohistochemistry staining of VEGF (an essential protein for angiogenesis and vasculogenesis) in the repaired tissues revealed that VEGF in the miR-210-treated group was intensely expressed in the repaired sites as compared to that in the control group ([Figure 3](#fig3){ref-type="fig"}C).Figure 3(A) Immunohistochemistry of isolectin B4 in both groups. Bar indicates 100 μm. (B) Vessel number in both groups. (C) Immunohistochemistry of vascular endothelial growth factor (VEGF) in both groups. Bar indicates 100 μm. \**p* \< 0.05. miR-210 = microRNA-210; VEGF = vascular endothelial growth factor; DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride) is a fluorescent stain that binds strongly to A-Trich regions in DNA.

DNA microarray analysis {#sec3.4}
-----------------------

The cDNA microarray analysis of tissues from the repaired sites of both groups was performed at 1 week after the procedure using 3D-Gene Rat Oligo chip 24k (Toray Industries Inc.). Gene ontology analysis revealed that the expression of genes related to cell proliferation, differentiation, and negative regulation of apoptosis was remarkably upregulated and gene expression related to negative regulation of cell proliferation, negative regulation of cell growth, and positive regulation of apoptosis was downregulated ([Table 1](#tbl1){ref-type="table"}). These results indicated that miR-210 could stimulate cell differentiation and proliferation as well as negatively regulate cell apoptosis in the repaired site of MCL. To confirm the effect of miR-210 in cell proliferation as well as to identify target cells of miR210 treatment in the repaired site, immunohistochemistry was performed. A lot of Ki67 (a marker of cell proliferation)-positive cells were observed in the repaired site of MCL in the miR-210-treated group as compared to that of the control group, and these cells were merged with isolectin B4- and collagen type 1-positive cells ([Figure 4](#fig4){ref-type="fig"}). Thus, miR-210 might increase endothelial cells and collagen type 1-producing cells during MCL healing. Pathway enrichment analysis showed that retinol metabolism, prostaglandin synthesis and regulation, adipogenesis, triacylglyceride synthesis, type 2 interferon signalling, and cholesterol metabolism were upregulated (\>2-fold change; [Table 2](#tbl2){ref-type="table"}).Figure 4Immunohistochemistry of isolectin B4, Ki67, and collagen type 1 in both groups. Bar indicates 100 μm. miR-210 = microRNA-210.Table 1The result of gene ontology analysis.**Up regulation (\>2 fold change)Gene count**GO:0045944: positive regulation of transcription from RNA polymerase II promoter281GO:0042493: response to drug181GO:0043066: negative regulation of apoptosis155GO:0008284: positive regulation of cell proliferation139GO:0045893: positive regulation of transcription, DNA-dependent137GO:0014070: response to organic cyclic compound126GO:0006355: regulation of transcription, DNA-dependent111GO:0000122: negative regulation of transcription from RNA polymerase II promoter105GO:0006351: transcription, DNA-dependent100GO:0030154: cell differentiation91GO:0045892: negative regulation of transcription, DNA-dependent90GO:0051384: response to glucocorticoid stimulus78GO:0007275: multicellular organismal development74GO:0007507: heart development65GO:0006357: regulation of transcription from RNA polymerase II promoter54  **Down regulation (\<0.5 fold change)Gene count**GO:0008285: negative regulation of cell proliferation129GO:0006355: regulation of transcription, DNA-dependent128GO:0043065: positive regulation of apoptosis113GO:0007275: multicellular organismal development100GO:0030308: negative regulation of cell growth100GO:0045893: positive regulation of transcription, DNA-dependent100GO:0007519: skeletal muscle tissue development92GO:0006811: ion transport81GO:0043066: negative regulation of apoptosis81GO:0030154: cell differentiation64GO:0042493: response to drug61GO:0006096: glycolysis56GO:0005975: carbohydrate metabolic process54GO:0006810: transport51Table 2The results of pathway enrichment analysis.MAPP nameGene numberZ ScorePermuteP\>2 fold change*1*Retinol metabolism85.4240*2*Prostaglandin synthesis and regulation74.930*3*Adipogenesis1020.06*4*Triacylglyceride synthesis32.130.065*5*Type II interferon signaling42.0790.066*6*Cholesterol metabolism32.0350.094\<0.5 fold change*1*Electron transport chain4412.5240*2*Striated muscle contraction2211.4050*3*TCA cycle169.260*4*Oxidative phosphorylation259.2240*5*Glycolysis and gluconeogenesis167.2850*6*Glycogen metabolism82.9670.007*7*Beta oxidation meta pathway82.9670.007*8*Fatty acid beta oxidation82.7660.014*9*Diurnally regulated genes with circadian orthologs92.6140.019*10*Mitochondrial LC-fatty acid beta-oxidation52.7750.02*11*Beta oxidation of unsaturated fatty acids33.3580.022*12*Fatty acid beta oxidation 162.2310.041

Discussion {#sec4}
==========

Previous reports showed that several therapeutic trials using cells, cytokines, and platelet-rich plasma for accelerating MCL healing were conducted.[@bib21], [@bib22], [@bib33] Among the cytokines for ligament healing, VEGF plays a crucial role in angiogenesis, a crucial event in the healing process of injured MCL.[@bib22] In the natural healing process of ligaments, the VEGF expression crested between 5 days and 9 days postinjury.[@bib17], [@bib34] Additional expression of VEGF such as local administration does not affect the mechanical properties, which indicated that proper levels of VEGF and other factors may be required for functional ligament healing.[@bib35], [@bib36] Another report demonstrated that local administration of peripheral blood-derived CD34+ cells could promote MCL healing via vasculogenesis.[@bib21] In this study, we have shown that local injection of dsmiR-210 could accelerate MCL healing. The ultimate failure load in the miR-210-treated group was significantly higher than that of the control group at 2 weeks. At 4 weeks, ultimate failure load in the miR-210-treated group was likely to be high compared to that in the control group, but there was no statistically significant difference. The ultimate failure load in both groups was almost the same as that in the sham group; therefore, the effect of the administration of dsmiR-210 on the mechanical properties might not be detected in the rat model. At 2 weeks, collagen type 1 expression and angiogenesis were upregulated in the miR-210-treated group. Most athletes with ligament injury generally can return to full competition 5--7 weeks after injury.[@bib5] Early intervention for the injured MCL would be important for upregulation of angiogenesis and synthesis of collagen type 1, subsequently yielding better mechanical properties. In this study, a single-dose injection was administered. However, even with a single-dose injection, the expression of many genes in the injected site was altered at 1 week. Previous reports showed that a single-dose injection of miRNA could enhance the therapeutic effects; therefore, only a single-dose injection to the injured MCL will be feasible.[@bib13], [@bib27], [@bib37], [@bib38] However, our study showed only one time point of injection. The effect of repeated injections of miR-210 on MCL healing, including the adverse effects, is unclear. As a single injection of miR-210 could enhance collagen type 1 expression, there is a possibility that repeated injections of miR-210 can show better results than a single injection. The results of this study suggested that local injection of miR-210 can be a potential novel treatment strategy to accelerate the healing of an injured ligament, thus enabling injured athletes to return to full competition earlier.

An advantage of miRNA therapy is that it does not require tissue harvesting, including isolation and purification of cells or platelet-rich plasma. Thus, miRNA therapy is simple in its construction and potentially used as a novel drug. Furthermore, multifactorial effects of miRNA for obtaining functional ligament properties will be expected as its targeting many genes based on computational analysis. In addition to its effect on angiogenesis, miR-210 has also been reported to play roles in other biological processes, including mitochondrial metabolism, DNA repair, regulation of apoptosis, and cell proliferation.[@bib25] Gene ontology enrichment analysis of our study indicated significant upregulation of genes that are positively involved in transcription, cell proliferation, and cell differentiation, as well as genes that negatively regulate apoptosis in the samples derived from miR-210-treated genes, as compared to those from the control group. These results suggested that gene expression related to tissue repair was upregulated by miR-210 treatment in the injured sites of MCL, an effect that seem to specifically stimulate angiogenesis and collagen type 1 production. Pathway enrichment analysis showed that retinol metabolism was activated by miR-210 administration during MCL healing. The retinol metabolism pathway plays an important role in normal development and disease.[@bib39] Retinoic acid, which is the main derivative of retinol (vitamin A), is essential for regulating several biological processes including differentiation, proliferation, and apoptosis. Moreover, retinoids regulate stem cell differentiation via transcription activation.[@bib40] The potential of retinoic acid in regenerative medicine has been examined.[@bib41] Thus, the results of this study are consistent with those reported in the literature. Further studies are needed to explore the role of retinoic acid in the healing process of MCL and its relationship with miR-210. In this study, microarray analysis was performed at 1 week postinjection because there was a significant difference in the histological findings at 2 weeks. The early change of the gene expression is important to analyse the mechanism of healing. Significant events such as angiogenesis in the tendon healing occur at around 1 week; therefore, we performed microarray analysis at 1 week.

For clinical application, the biological safety of miRNA treatment should be validated. Expressions of miRNA have a role in several human diseases such as cancer. In this study, no adverse effects were observed, but we could not confirm the distribution of administered miR-210 in the rats. It has been reported that miR-210 negatively regulates cancer cell proliferation.[@bib42] However, further studies are needed to examine its safety, including investigation of its adverse effects, prior to its application in clinical settings. Clinical trials of miRNA replacement therapy or antisense oligonucleotides of miRNA are currently ongoing; hence, miRNA targeting therapy is gradually being recognised.[@bib43], [@bib44]

In conclusion, our study showed that local injection of miR-210 could accelerate MCL healing. Further studies are required to gain more detailed insights into its mechanism of action. Local injection of miR-210 into the injured MCL is one of the potential therapeutic options in the future since accumulating evidence suggested that the effectiveness and safety of miRNA therapy are promising.
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